Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | LPO | P22079 | 2/20 | 0.79 |
| ▸ | MPO | P05164 | 1/20 | 0.79 |
| ▸ | TPO | P07202 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.79 |
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYB5R3 | P00387 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10489579 | 0.95 | KMT2A (1.00) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL11739128 | 0.93 | KMT2A (0.97) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL15752987 | 0.93 | KMT2A (0.97) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL29948466 | 0.93 | KMT2A (0.97) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL6996841 | 0.93 | KMT2A (0.97) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL11736351 | 0.93 | KMT2A (0.97) | KMT2ALPOMPOTPOTSHR | |
| Propylthiouracil SCHEMBL5493716 | 0.89 | LPO (1.00) | KMT2ALPOMPOTPOTSHR | |
| Propylthiouracil SCHEMBL41239 | 0.89 | LPO (1.00) | KMT2ALPOMPOTPOTSHR | |
| Propylthiouracil SCHEMBL27995248 | 0.87 | LPO (0.96) | KMT2ALPOMPOTPOTSHR | |
| SCHEMBL11582733 | 0.86 | KMT2A (0.82) | KMT2ALPOMPOTPOTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021087408-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | disclosed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | disclosed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | disclosed |
| WO-2012115479-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
| EP-0930534-A1 | A black-white image forming method | KONICA CORPORATION (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | KMT2A 4017/4885LPO 2130/4885MPO 3541/4885 |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | KMT2A 4017/4885LPO 2130/4885MPO 3541/4885 |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | KMT2A 4017/4885LPO 2130/4885MPO 3541/4885 |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | KMT2A 4008/4885LPO 874/4885MPO 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.